HomeCompareIGXT vs QYLD

IGXT vs QYLD: Dividend Comparison 2026

IGXT yields 1176.47% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IGXT wins by $78814195.18M in total portfolio value
10 years
IGXT
IGXT
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full IGXT calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — IGXT vs QYLD

📍 IGXT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIGXTQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IGXT + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IGXT pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IGXT
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, IGXT beats the other by $57,395,146,060,314.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IGXT + QYLD for your $10,000?

IGXT: 50%QYLD: 50%
100% QYLD50/50100% IGXT
Portfolio after 10yr
$39407097.61M
Annual income
$33,761,850,629,373.85/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IGXT right now

IGXT
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-23.8
Piotroski
4/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IGXT buys
0
QYLD buys
0
No recent congressional trades found for IGXT or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIGXTQYLD
Forward yield1176.47%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$78814195.20M$25.4K
Annual income after 10y$67,523,701,253,088.38$5,659.31
Total dividends collected$77969765.27M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: IGXT vs QYLD ($10,000, DRIP)

YearIGXT PortfolioIGXT Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$128,347$117,647.06$10,352$1,192.36+$118.0KIGXT
2$1,548,514$1,411,182.61$10,830$1,347.57+$1.54MIGXT
3$17,569,052$15,912,142.01$11,460$1,539.07+$17.56MIGXT
4$187,523,354$168,724,468.35$12,275$1,777.84+$187.51MIGXT
5$1,883,716,681$1,683,066,692.55$13,323$2,078.95+$1883.70MIGXT
6$17,816,329,317$15,800,752,468.33$14,667$2,463.34+$17816.31MIGXT
7$158,731,384,105$139,667,911,735.60$16,396$2,960.57+$158731.37MIGXT
8$1,332,782,916,056$1,162,940,335,063.89$18,631$3,612.97+$1332782.90MIGXT
9$10,551,863,503,163$9,125,785,782,982.70$21,548$4,482.15+$10551863.48MIGXT
10$78,814,195,201,473$67,523,701,253,088.38$25,398$5,659.31+$78814195.18MIGXT

IGXT vs QYLD: Complete Analysis 2026

IGXTStock

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Full IGXT Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this IGXT vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IGXT vs SCHDIGXT vs JEPIIGXT vs OIGXT vs KOIGXT vs MAINIGXT vs XYLDIGXT vs JEPQIGXT vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.